SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Exploration of Non-Replicating Mycobacterium Tuberculosis In Vitro System Through Mathematical Modelling | A. SchipaniView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016High drug tolerance of Mycobacterium tuberculosis in caseum | J. SarathyView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Rifapentine plus Isoniazid Eradicates Mycobacterium tuberculosis among Rhesus Macaques with Latent TB Infection | H. BlumbergView Slideset
AOAndrew OwenBSS, MSC, PhD, FSBSlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Long acting (LA) drug delivery in TB treatment | Andrew Owen, BSS, MSC, PhD, FSBView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Simulation of long-acting administration of antituberculosis agents using pharmacokinetic modelling | R. RajoliView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016A translational modelling and simulations approach to exploit pre-clinical tuberculosis data | S. WichaView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016The relationship between pyrazinamide pharmacokinetics (PK) and microbiologic outcomes in patients with pulmonary TB receiving standard- or high-dose rifampicin: PK/PD results from TBTC trials 27 and 28 and PanACEA MAMS | K. DooleyView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Application Of A Multi-Compartment Permeability-Limited Lung Model To Predict Lung Concentrations Of Moxifloxacin In Virtual Human Subjects | O. HatleyView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Development of a novel multi-compartment granuloma model to predict local drug distribution and its impact on pharmacodynamics and disease progression in tuberculosis. | I. GardnerView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Lost in translation: learning from preclinical data | Gerry DaviesView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016A Need for altering Tuberculosis Dosing Regiments for patients with HIV-associated Tuberculous Meningitis | G. AljayyoussiView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Sub-therapeutic concentrations of anti-tuberculosis drugs in children when treated according to indian dosing recommendation | B. GuiastrennecView Slideset
